Biology Informs Treatment Choices in Diffuse Large B Cell Lymphoma
| Autor: | Ricardo C.T. Aguiar, Matthew James Butler |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
0301 basic medicine
Cancer Research Immune checkpoint inhibitors medicine.medical_treatment B-cell receptor Receptors Antigen B-Cell Biology Targeted therapy Proto-Oncogene Proteins c-myc Antibodies Monoclonal Murine-Derived 03 medical and health sciences immune system diseases hemic and lymphatic diseases Antineoplastic Combined Chemotherapy Protocols Tumor Microenvironment medicine Humans Cyclophosphamide neoplasms Neovascularization Pathologic Treatment choices breakpoint cluster region medicine.disease Lymphoma Gene Expression Regulation Neoplastic 030104 developmental biology Proto-Oncogene Proteins c-bcl-2 Oncology Doxorubicin Drug Resistance Neoplasm Vincristine Cancer research Prednisone Lymphoma Large B-Cell Diffuse Rituximab Diffuse large B-cell lymphoma |
| Zdroj: | Trends in Cancer. 3:871-882 |
| ISSN: | 2405-8033 |
| DOI: | 10.1016/j.trecan.2017.09.008 |
| Popis: | The effective deployment of rationally developed therapies for diffuse large B cell lymphoma (DLBCL) requires rapid assimilation of new biological data. Within this framework, here we address topical issues at the intersection of DLBCL biology and the clinic. We discuss targeting of B cell receptor (BCR) signaling, with emphasis on identifying patients who may benefit from this maneuver and how to best achieve it. We address strategies to modulate the DLBCL microenvironment, including the use of immune checkpoint inhibitors in selected DLBCL subsets, and the potential activity of alternative antiangiogenic therapies. Lastly, we highlight the emerging recognition of MYC and BCL2 coexpression as the most robust predictor of DLBCL outcome, and discuss rationally conceived experimental approaches to treat these high-risk patients. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|